Hemispherx BioPharma Issues Press Release on Phase 2 Study Collaboration

Hemispherx BioPharma, trading on NYSE American under the symbol HEB, has recently made public a pivotal collaboration through a press release issued on February 11, 2025. The company’s subsidiary, AIM ImmunoTech Inc., unveiled a dedicated segment aimed at providing insights into the Phase 2 Study of Ampligen and AstraZeneca’s Imfinzi. This study focuses on their potential combination treatment for late-stage pancreatic cancer.

The interview showcased in the segment featured Thomas K. Equels, the CEO of AIM ImmunoTech, and Professor Casper H.J. van Eijck, MD, PhD. The engaging dialogue highlighted the recent approval by the Erasmus Medical Center Safety Committee to move forward with the Phase 2 Study.

The Erasmus Medical Center’s green light followed a detailed review of safety data from the Phase 1 trial, indicating favorable tolerance levels with no severe adverse events or dose-related toxicities associated with the combined treatment. The collaborative efforts surrounding the Phase 2 Study signify a significant step forward in the pursuit of innovative therapies for late-stage pancreatic cancer.

Encouragingly, the press release also emphasized the cautionary note regarding forward-looking statements pursuant to the Private Securities Litigation Reform Act of 1995. This act underscores the importance of acknowledging the risks and uncertainties involved in such endeavors. The company urges investors to consider these factors and advisory statements meticulously in light of the information presented.

Furthermore, AIM ImmunoTech Inc., a dedicated immuno-pharma company, continues to focus on pioneering research and development efforts aimed at tackling various cancer types, immune disorders, and viral diseases, including the ongoing battle against COVID-19. At the forefront of their initiatives is Ampligen, a distinguished investigational drug showing broad-spectrum activity in clinical trials for critical diseases.

For additional details on AIM ImmunoTech Inc.’s ongoing projects and initiatives, interested parties are invited to visit their official website. The company encourages engagement and interaction with stakeholders through various platforms including X, LinkedIn, and Facebook.

It is crucial to note that the contents of the press release reveal strategic forward-looking goals and aspirations. While current achievements and milestones are commendable, they do not guarantee future success in gaining approval for Ampligen as a therapeutic option for pancreatic cancer. Investors are advised to remain attentive to the evolving landscape and potential risks as disclosed in the company’s regulatory filings.

For any investor-related inquiries, the contact person provided is Jenene Thomas of JTC Team, LLC.

This news indicates an exciting and proactive development in the ongoing efforts at Hemispherx BioPharma and its subsidiary, AIM ImmunoTech Inc., towards innovative therapeutic treatments.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Hemispherx BioPharma’s 8K filing here.

Hemispherx BioPharma Company Profile

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).